RESUMEN
BACKGROUND: Intralesional injection of sterile medications remains a mainstay in dermatology, enabling a tailored, low-cost, in-office therapy. After the 2012 United States outbreak of fungal meningitis from contaminated intrathecally administered corticosteroids, there has been increased regulation of in-office compounding, regardless of the administration route. Studies demonstrating the safety data of in-office corticosteroid compounding for intradermal or subcutaneous use are lacking. OBJECTIVE: To assess the incidence of infection caused by compounded in-office intralesional triamcinolone. METHODS: A retrospective medical record review identified patients who received in-office intralesional corticosteroid injections in 2016. Medical documentation within 30 days of injection was reviewed for suspected infection. RESULTS: The records of 4370 intralesional triamcinolone injections were assessed, of which 2780 (64%) were compounded triamcinolone with bacteriostatic saline. We identified 11 (0.25%) suspected localized infections, with 4 of the 11 in the compounding cohort. Of these, 7 of 11 occurred after injection of an "inflamed cyst." No hospitalizations or deaths occurred. No temporal or locational relationships were identified. LIMITATIONS: This study was limited to 2 academic institutions. A 30-day postinjection time frame was used. CONCLUSION: In-office compounding for intralesional dermal and subcutaneous administration is safe when sterile products are used by medical practitioners. There is no increased risk of compounded triamcinolone relative to noncompounded triamcinolone.
Asunto(s)
Antiinflamatorios/administración & dosificación , Composición de Medicamentos/estadística & datos numéricos , Enfermedades Cutáneas Infecciosas/epidemiología , Triamcinolona/administración & dosificación , Instituciones de Atención Ambulatoria , Humanos , Incidencia , Inyecciones Intralesiones/estadística & datos numéricos , Inyecciones Subcutáneas/estadística & datos numéricos , Registros Médicos , Michigan/epidemiología , Estudios Retrospectivos , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades Cutáneas Infecciosas/etiologíaRESUMEN
CONTEXT: In patients with obesity, intramuscular injections may be deposited subcutaneously due to an increase in gluteal fat. We aimed to use abdominal CT done in our institute for gluteal fat thickness to test our hypothesis. MATERIALS AND METHODS: After IRB approval, CT scans of the abdomen and pelvis of the past 6 months were analyzed. The thickness of gluteal region subcutaneous fat was measured in a standardized manner. RESULTS: Out of 700 CT scans, studied, 476 were males and 224 were females. The average gluteal fat thickness was 2.34 cm +/- 1 cm. The average fat thickness in males was 1.98 cm +/- 0.98 cm whereas in females was 3.0 cm +/- 1.2 cm. Subcutaneous granulomas were seen in 17 cases and one injection granuloma in the intramuscular plane. CONCLUSION: A significant number of female patients had increased gluteal fat thickness beyond the reach of routinely used needles. The medications in these patients will thus be unintentionally injected to subcutaneous plane, possibly altering the pharmacokinetics.
Asunto(s)
Nalgas/diagnóstico por imagen , Granuloma/etiología , Inyecciones Intramusculares , Grasa Subcutánea/diagnóstico por imagen , Tejido Adiposo/anatomía & histología , Tejido Adiposo/diagnóstico por imagen , Adulto , Anciano , Índice de Masa Corporal , Nalgas/anatomía & histología , Femenino , Granuloma/diagnóstico por imagen , Humanos , Inyecciones Intramusculares/métodos , Inyecciones Intramusculares/estadística & datos numéricos , Inyecciones Subcutáneas/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Agujas , Estudios Retrospectivos , Distribución por Sexo , Grosor de los Pliegues Cutáneos , Tomografía Computarizada por Rayos X/métodos , Adulto JovenRESUMEN
PURPOSE: Utilization reports on immunoglobulin (Ig) use for immunodeficiency in the United States (U.S.) have focused on prescribing practices in hospitals. There have been no large-scale reports on Ig use for immune deficiency in the home. We investigated the use of Ig in 3,187 subjects diagnosed with primary immunodeficiency. METHODS: Cross-sectional data on 4,580 subjects in the U.S. receiving Ig in 2011 was obtained from a major home care provider. Demographics, route, dose, and frequency of Ig use by subjects with ICD-9 coded primary immunodeficiencies were analyzed. RESULTS: Of 4,580 subjects, 3,187 had ICD-9 codes suggesting primary immunodeficiencies; 1,939 (60.8 %) were females and 1,248 (39.2 %) were males, with age ranging from 0 to 95 years. The predominant diagnoses were: common variable immunodeficiency (279.06; n=1,764; 55.3 %), hypogammaglobulinemia (279.00; n=635; 19.9 %), unspecified immunity deficiency (279.3; n=286; 9 %), other selective Ig deficiencies (279.03; n=171; 5.4 %), and agammaglobulinemia (279.04; n=127; 4 %). 54 % of subjects received Ig by the subcutaneous (SC) route, and 46 % by intravenous (IV) route, with more SC use by older subjects. The mean dose prescribed was 483 mg/kg/month, but less Ig was ordered for subjects on SCIg (409 mg/kg/month), as compared to subjects on IVIg (568 mg/kg/month). A highly significant inverse correlation between increasing age and dosage of Ig ordered was found (P= <.0001). CONCLUSION: Analysis of home care use of Ig in primary immune deficiency revealed that the SC route was prescribed more than the IV route, especially for older patients. By either method of administration, less immunoglobulin was prescribed for older subjects.
Asunto(s)
Inmunodeficiencia Variable Común/tratamiento farmacológico , Inmunodeficiencia Variable Común/inmunología , Servicios de Atención de Salud a Domicilio/estadística & datos numéricos , Servicios de Atención de Salud a Domicilio/tendencias , Inmunoglobulinas Intravenosas/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Inmunodeficiencia Variable Común/epidemiología , Estudios Transversales , Femenino , Humanos , Inmunoglobulinas Intravenosas/administración & dosificación , Lactante , Recién Nacido , Inyecciones Intravenosas/estadística & datos numéricos , Inyecciones Intravenosas/tendencias , Inyecciones Subcutáneas/estadística & datos numéricos , Inyecciones Subcutáneas/tendencias , Masculino , Persona de Mediana Edad , New York/epidemiología , Adulto JovenRESUMEN
INTRODUCTION: Vaseline self-injection into the penis is currently a popular procedure in prisons. Since such injections are illegal, severe complications of the procedure can often remain hidden. AIM: To identify the incidence, motivation, and morbidity of Vaseline self-injection into the penis among inmates. METHODS: A total of 4,735 inmates at the largest Hungarian prisons were asked to complete a questionnaire relating to their sexual life, whether they had self-injected Vaseline into their penis, the motivation leading them to resort to Vaseline self-injection, any complications observed and the level of satisfaction attained. MAIN OUTCOME MEASURES: A 17-point questionnaire on the circumstances, motivations, and complications of Vaseline self-injection among prisoners. RESULTS: Of the 1,905 responders, 15.7% admitted Vaseline self-injection. Only around one-fifth of the Vaseline injected subjects had not been satisfied with the original size of their penis and their sexual life up to the time of the injection, a proportion similar to that among Vaseline nonusers. While the satisfaction with the sexual life became significantly worse after the Vaseline injection, the satisfaction with the penis size did not change and an erectile dysfunction developed de novo in 21.4% of cases. The most common motivation for self-injection was a recommendation by another inmate; it was rarely recommended by a sexual partner. Complications had developed among 25.4% of the Vaseline users and 50.3% of them were not satisfied with the result of the Vaseline injection. Of the Vaseline users, 22.4% regretted the self-injection, while the rate among those who had developed complications was 53%. CONCLUSIONS: The self-injection of Vaseline into the penile skin proved to be somewhat of a trend among these inmates. The complications depended mainly on the amount of Vaseline injected, the poor hygienic circumstances, and the personal tolerability. Increased awareness is needed for the prevention of this social, psychological, and physical problem.
Asunto(s)
Disfunción Eréctil/inducido químicamente , Enfermedades del Pene/inducido químicamente , Pene/efectos de los fármacos , Vaselina/administración & dosificación , Vaselina/toxicidad , Prisiones/estadística & datos numéricos , Automedicación/estadística & datos numéricos , Adolescente , Adulto , Anciano , Estudios Transversales , Disfunción Eréctil/epidemiología , Gangrena/inducido químicamente , Gangrena/epidemiología , Granuloma/inducido químicamente , Granuloma/epidemiología , Humanos , Hungría , Incidencia , Inyecciones Subcutáneas/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Motivación , Necrosis , Enfermedades del Pene/epidemiología , Fimosis/inducido químicamente , Fimosis/epidemiología , Piel/efectos de los fármacos , Piel/patología , Úlcera Cutánea/inducido químicamente , Úlcera Cutánea/epidemiología , Encuestas y Cuestionarios , Adulto JovenRESUMEN
AIM: Continuous subcutaneous insulin infusion (CSII) is used as an option in patients with diabetes failing to multiple daily injections (MDI). Psychological factors may play a relevant role in the failure to attain therapeutic goals in patients on MDI. This could lead to an overrepresentation of psychopathology in patients treated with CSII. METHODS: A consecutive series of 100 patients with type 1 diabetes was studied, collecting main clinical parameters and assessing psychopathology with the self-reported questionnaire Symptom Checklist 90-revised. Patients on CSII were then compared with those on MDI. RESULTS: Of the 100 enrolled patients, 44 and 56 were on CSII and MDI, respectively. Among men, those on CSII were younger than those on MDI; conversely, no difference in age was observed in women. Women on CSII showed higher scores on most Symptom Checklist 90 subscales than those on MDI, whereas no differences were observed in men. CONCLUSION: Women with type 1 diabetes treated with CSII display higher levels of psychopathology than those on MDI. This is probably the consequence of the fact that patients selected for CSII are those failing to MDI. Higher levels of psychopathology could represent a limit for the attainment and maintenance of therapeutic goals with CSII.
Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 1/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Sistemas de Infusión de Insulina/estadística & datos numéricos , Insulina/administración & dosificación , Trastornos Mentales/epidemiología , Adulto , Distribución por Edad , Comorbilidad , Femenino , Humanos , Hipoglucemiantes/administración & dosificación , Infusiones Subcutáneas/estadística & datos numéricos , Inyecciones Subcutáneas/estadística & datos numéricos , Italia/epidemiología , Masculino , Cooperación del Paciente/psicología , Cooperación del Paciente/estadística & datos numéricos , Prevalencia , Factores de Riesgo , Distribución por Sexo , Factores Sexuales , Resultado del TratamientoRESUMEN
OBJECTIVES: To evaluate the health-related quality of life (HRQoL) of children and adolescents with type 1 diabetes (T1DM) in Kuwait using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scale and PedsQL 3.0 Diabetes Module, and to identify the risk factors associated with unsatisfactory QoL and their effects on metabolic control. SUBJECTS AND METHODS: A total of 436 patients (2-18 years) with T1DM (>6 months) and 389 healthy controls, with the parents of both groups, completed the Arabic Generic Core Scale. Those with T1DM also completed the Arabic Diabetes Module. RESULTS: The mean total score of the PedsQL Diabetes Module was 70.2 ± 9.8 reported by children and 59.9 ± 11.1 reported by parents (higher scores indicate better QoL). Young age and long duration of diabetes were associated with poor QoL (p < 0.001). Boys had better total scores than girls in most age groups (70.3 ± 9.3 vs. 52.3 ± 7.2, p < 0.001); however, girls did better than boys regarding treatment barriers and adherence (71.3 ± 7.8 vs. 68.1 ± 6.2, p < 0.005). Higher HbA1c values were associated with lower QoL scores (31.1 ± 5.1 at HbA1c of 15% vs. 82.5 ± 6.1 at HbA1c of 6%, p < 0.0001). CONCLUSION: HRQoL of children and adolescents with T1DM was consistently poorer than controls. Parents consistently reported poorer QoL scores than their children. We recommend that more support should be provided for the care of children with diabetes in Kuwait.
Asunto(s)
Diabetes Mellitus Tipo 1/epidemiología , Diabetes Mellitus Tipo 1/psicología , Calidad de Vida , Adolescente , Factores de Edad , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Hemoglobina Glucada/análisis , Humanos , Hipoglucemiantes/uso terapéutico , Inyecciones Subcutáneas/estadística & datos numéricos , Insulina/uso terapéutico , Kuwait , Masculino , Padres , Autoinforme , Factores SexualesRESUMEN
Purpose: Immunoglobulin (Ig) replacement therapy is an important life-saving treatment modality for patients with primary antibody immune deficiency disorders (PAD). IVIG and SCIg are suitable alternatives to treat patients with PAD but vary in key ways. Existing evidence on patient preferences for Ig treatments given the complexities associated with IVIG and SCIg treatment is limited and fails to account for variations in preferences across patients. For this reason, we sought to evaluate PAD patient preferences for features of IVIG and SCIg across different patient characteristics. Materials and Methods: 119 PAD patients completed a discrete-choice experiment (DCE) survey. The DCE asked respondents to make choices between carefully constructed treatment alternatives described in terms of generic treatment features. Choices from the DCE were analyzed to determine the relative influence of attribute changes on treatment preferences. We used subgroup analysis to evaluate systematic variations in preferences by patients' age, gender, time since diagnosis, and treatment experience. Results: Patients were primarily concerned about the duration of treatment side effects, but preferences were heterogeneous. This was particularly true around administration features. Time since diagnosis was associated with an increase in patients' concerns with the number of needles required per infusion. Also, patients appear to prefer the kind of therapy they are currently using which could be the result of properly aligned patient preferences or evidence of patient adaptive behavior. Conclusions: Heterogeneity in preferences for Ig replacement treatments suggests that a formal shared decision making process could have an important role in improving patient care.
Asunto(s)
Inmunización Pasiva/métodos , Inmunoglobulinas Intravenosas/administración & dosificación , Prioridad del Paciente/estadística & datos numéricos , Enfermedades de Inmunodeficiencia Primaria/tratamiento farmacológico , Adolescente , Adulto , Anciano , Femenino , Humanos , Infusiones Intravenosas/estadística & datos numéricos , Inyecciones Subcutáneas/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Enfermedades de Inmunodeficiencia Primaria/inmunología , Encuestas y Cuestionarios , Resultado del Tratamiento , Adulto JovenRESUMEN
The increasing potential for radiation exposure from nuclear accidents or terrorist activities has intensified the need to develop pharmacologic countermeasures against injury from total body irradiation (TBI). Many initial experiments to develop and test these countermeasures utilize murine irradiation models. Yet, the route of drug administration can alter the response to irradiation injury. Studies have demonstrated that cutaneous injuries can exacerbate damage from radiation, and thus surgical implantation of osmotic pumps for drug delivery could adversely affect the survival of mice following TBI. However, daily handling and injections to administer drugs could also have negative consequences. This study compared the effects of subcutaneous needlesticks with surgical implantation of osmotic pumps on morbidity and mortality in a murine model of hematopoietic acute radiation syndrome (H-ARS). C57BL/6 mice were sham irradiated or exposed to a single dose of 7.7 Gy 60Co TBI. Mice were implanted with osmotic pumps containing sterile saline seven days prior to irradiation or received needlesticks for 14 days following irradiation or received no treatment. All irradiated groups exhibited weight loss. Fewer mice with osmotic pumps survived to 30 days post irradiation (37.5%) than mice receiving needlesticks or no treatment (70% and 80%, respectively), although this difference was not statistically significant. However, mice implanted with the pump lost significantly more weight than mice that received needlesticks or no treatment. These data suggest that surgical implantation of a drug-delivery device can adversely affect the outcome in a murine model of H-ARS.
Asunto(s)
Síndrome de Radiación Aguda/tratamiento farmacológico , Bombas de Infusión Implantables/estadística & datos numéricos , Inyecciones Subcutáneas/estadística & datos numéricos , Irradiación Corporal Total/normas , Animales , Modelos Animales de Enfermedad , Femenino , Ratones , Ratones Endogámicos C57BLRESUMEN
BACKGROUND: The MARTE study investigated the demographic, clinical, and therapeutic characteristics of rheumatoid arthritis (RA) patients ongoing methotrexate (MTX) treatment for longer than 8 years. METHODS: This cross-sectional, observational study considered 587 RA patients from 67 Rheumatology Units across Italy. Data collected included demographic, clinical, and therapeutic characteristics, focusing on MTX prescription patterns (route of administration, dosing regimens, treatment duration, and discontinuation). RESULTS: As initial therapy, 90.6% of patients received one conventional synthetic Disease Modifying Anti Rheumatic Drug (csDMARD), with treatment started within the first 3 months from diagnosis in half of the patients. MTX was the first csDMARD in 46.2% of patients. The prevalent route of administration at diagnosis was the intramuscular (60.5%), while at study entry (baseline) 57.6% were receiving subcutaneous MTX. Patients who required a higher MTX dose at study entry were those who received a significantly lower starting MTX dose (P<0.001). Significantly higher MTX doses were currently required in men (P<0.001), current smokers (P=0.013), and overweight patients (P=0.028), whereas patients on oral therapy received significantly lower doses of MTX (P<0.001). CONCLUSIONS: The MARTE study confirms once again the potential of the proper use of MTX in the treatment of RA. Data from our study suggest that a higher dose of MTX should be used since the first stages in overweight patients, men, and smokers.
Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Metotrexato/uso terapéutico , Anciano , Antirreumáticos/administración & dosificación , Estudios Transversales , Femenino , Humanos , Inyecciones Intramusculares/estadística & datos numéricos , Inyecciones Subcutáneas/estadística & datos numéricos , Italia , Masculino , Metotrexato/administración & dosificación , Posmenopausia , Factores Sexuales , Fumadores , Factores Socioeconómicos , Factores de TiempoRESUMEN
INTRODUCTION: Daratumumab is an anti-CD38 monoclonal antibody widely used for treating patients with newly diagnosed or relapsed/refractory multiple myeloma. The subcutaneous formulation of daratumumab was developed with the purpose of minimizing the treatment burden (to patients and health care system) associated with intravenous daratumumab. Given its recent approval, there is a knowledge gap regarding the best practices that should be instituted for safe administration of subcutaneous daratumumab. METHODS: A retrospective chart review was performed from August 2020 until November 2020 to identify patients either switched to or treated upfront (daratumumab naive) with any subcutaneous daratumumab-based treatment regimen. All patients received appropriate premedications per institutional standards of care. The study end points were to report real-world data regarding administration-related reaction rates (at or following discharge from infusion center), as well as compare their incidence rates to those noted in the COLUMBA study (historical cohort). RESULTS: The study included 58 patients, of whom 38% (n = 22) were daratumumab naive. The majority (84%, n = 49) received subcutaneous daratumumab in combination with various antimyeloma regimens. There were no cases of administration-related reactions at infusion center or after discharge irrespective of previous exposure to intravenous daratumumab. None of the patients included herein required rescue home medications or visited the emergency department within 24 to 48 hours after subcutaneous daratumumab administration. These translated into a significant difference in incidence of administration-related reactions compared with historical cohort (0% vs. 13%, P = .003). CONCLUSION: Subcutaneous daratumumab was extremely well tolerated and could be safely administered without need for monitoring or rescue home medications.
Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Reacción en el Punto de Inyección/epidemiología , Mieloma Múltiple/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina/normas , Adulto , Anticuerpos Monoclonales/efectos adversos , Femenino , Humanos , Incidencia , Infusiones Intravenosas/efectos adversos , Infusiones Intravenosas/normas , Infusiones Intravenosas/estadística & datos numéricos , Infusiones Intravenosas/tendencias , Reacción en el Punto de Inyección/etiología , Inyecciones Subcutáneas/efectos adversos , Inyecciones Subcutáneas/normas , Inyecciones Subcutáneas/estadística & datos numéricos , Inyecciones Subcutáneas/tendencias , Masculino , Oncología Médica/normas , Oncología Médica/tendencias , Persona de Mediana Edad , Pautas de la Práctica en Medicina/tendencias , Estudios RetrospectivosRESUMEN
Drugs delivery by subcutaneous injection is often the last resort/appeal for a doctor anxious to limit the aggressive and invasive treatments, particularly within palliative care. A review was made to list the drugs which can be administered by this route. Concerned antibiotics are teicoplanin, netilmicin and gentamicin with a risk of skin necrosis for aminoglycosids. Midazolam is useful in various indications and can be associated with morphine in case of dyspnoea. Data about subcutaneous injection of dexamethasone, clonazepam, haloperidol and levomepromazine are published; it is the same for fentanyl, nefopam, ondansetron and metoclopramide. The subcutaneous injection of these quoted drugs is possible, but requires further studies.
Asunto(s)
Inyecciones Subcutáneas/estadística & datos numéricos , Cuidados Paliativos/métodos , Contraindicaciones , Erupciones por Medicamentos/etiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , Preparaciones Farmacéuticas/administración & dosificación , FarmacocinéticaRESUMEN
OBJECTIVES: to describe the experience of conducting workshops for teaching the subcutaneous fluid infusion therapy in palliative care patients. METHODS: experience report based on four workshops with a workload of nine hours each, addressing the teaching, implementation of the technique, and management in the use of subcutaneous fluid infusion therapy in patients in palliative care. The host institution was a private hospital, which had two care units in the state of Rio de Janeiro. RESULTS: we identified little knowledge about the theme. Due to the dynamics used, the workshops made it possible to qualify the participants to perform and manage the subcutaneous route in palliative care environments. CONCLUSIONS: the workshops were an important means of training, qualification, and dissemination of nursing care in a palliative care environment. The resources used to enable the qualification in the execution and management of the presented technique.
Asunto(s)
Certificación/métodos , Inyecciones Subcutáneas/enfermería , Asistentes de Enfermería/educación , Cuidados Paliativos/métodos , Certificación/estadística & datos numéricos , Humanos , Inyecciones Subcutáneas/estadística & datos numéricos , Asistentes de Enfermería/estadística & datos numéricos , Cuidados Paliativos/estadística & datos numéricosRESUMEN
OBJECTIVE: This study aims to evaluate patient's preferences in the choice of their therapy and the factors that influence this choice. METHODS: This cross-sectional study enrolled 101 outpatients with Crohn's disease or ulcerative colitis. The inclusion criteria were age ≥18 years and no previous exposure to biological therapy. Patients' preferences were assessed through questions that addressed the preferred mode of administration (oral, subcutaneous, or intravenous) and the factors that determined the choice of medication (efficacy, medical indication, fear of medication, convenience, mode of application, and personal doctors' indication). RESULTS: The mean age was 43.6±13.5 years, 75.3% were female, and 81.2% were cases of ulcerative colitis. Regarding the mode of administration, the majority of patients preferred oral (87.1%), followed by intravenous (6.93%) and subcutaneous (5.94%) medications. The reasons were "I prefer to take it at home" (42.57%), "I have more freedom" (36.63%), "I don't like self-application" (29.70%), and "I believe it works better" (19.80%). Younger patients and patients in clinical disease activity preferred intravenous mode compared to the oral route (P<0.05). Doctor's opinion (98%) was an important factor associated with the medication choice. CONCLUSION: Oral route was the preferred mode of administration and most patients took their physician's opinion into account in their choice of medication.
Asunto(s)
Administración Oral , Colitis Ulcerosa/tratamiento farmacológico , Fármacos Gastrointestinales/administración & dosificación , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Inyecciones Subcutáneas/estadística & datos numéricos , Prioridad del Paciente , Satisfacción del Paciente , Adulto , Anciano , Terapia Biológica , Brasil , Estudios Transversales , Femenino , Fármacos Gastrointestinales/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Encuestas y CuestionariosRESUMEN
INTRODUCTION: Algeria has more than 1.7 million diabetic patients on to whom a descriptive assessment particularly on the insulin usage behaviors has not yet been initiated, although is needed. This study aims to provide a descriptive analysis of how Algerian diabetic patients perceive and apply insulin injection techniques. METHODS: using the "patient" questionnaire within the Injection Technique Questionnaire (ITQ) 2016 survey, this study assessed the insulin injection practices of 100 patients recruited over a seven-month period in western Algeria at the Tlemcen University Hospital Center. The results of this study are compared to those of the ITQ 2016 survey. RESULTS: pens are the instruments of injection for 98% of Algerians who continue to use mostly long needles of 6- and 8-mm, although 4mm needles are the recommended safer option. Insulin analogues (fast and basal) are plebiscite. Arms and thighs are the preferred injection sites; the abdomen (the preferred site elsewhere) is neglected for reasons to be investigated. The correct re-suspension technique for cloudy insulin is unknown. Extensive pen needle re-use (10+ times) for over half of the patients exposes them to both higher intramuscular (IM) injection risk and lipohypertrophy (LH). Injection training is performed in Algeria by the diabetologist. CONCLUSION: this study describes for the first time Algerian patients´ insulin injection technique. It highlights their skills and identifies many deficiencies which patients and professionals must correct given the issues in this area.
Asunto(s)
Insulina/administración & dosificación , Agujas , Prioridad del Paciente/estadística & datos numéricos , Adulto , Anciano , Argelia/epidemiología , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/epidemiología , Femenino , Conocimientos, Actitudes y Práctica en Salud , Humanos , Reacción en el Punto de Inyección/epidemiología , Reacción en el Punto de Inyección/etiología , Inyecciones Intramusculares/efectos adversos , Inyecciones Subcutáneas/efectos adversos , Inyecciones Subcutáneas/métodos , Inyecciones Subcutáneas/estadística & datos numéricos , Lipodistrofia/inducido químicamente , Lipodistrofia/epidemiología , Masculino , Persona de Mediana Edad , Agujas/efectos adversos , Agujas/estadística & datos numéricos , Encuestas y Cuestionarios , Adulto JovenRESUMEN
BACKGROUND: It seems that more erythropoietin (EPO) is required when given intravenously (IV) than when given subcutaneously (SC). Estimates of the magnitude of this difference vary widely, impeding development of economic models in this area. Concerns about pure red cell aplasia led our program to switch from SC to IV EPO, so we studied the impact of this change on the cost of anemia therapy. METHODS: All in-center hemodialysis patients who had received EPO for at least 3 months prior to and following conversion to IV EPO were studied. Data was obtained retrospectively for 1 year prior to and prospectively for 1 year following conversion. The costs of anemia therapy (EPO, transfusions and iron) were calculated from the hospital's perspective. RESULTS: 158 patients were studied. One month after switching, the hemoglobin fell significantly, reaching a nadir at 3 months. This triggered more use of EPO, iron and transfusions. By month 7 hemoglobin levels had returned to initial levels, with a median rise in EPO dose of 1,250 units/week (p < 0.001). After the switch, the median rise in total anemia therapy costs was 13.1% (CAD 665/patient-year, p < 0.01). CONCLUSIONS: Conversion of EPO from SC to IV dosing increased the costs of anemia therapy at our center.
Asunto(s)
Anemia/tratamiento farmacológico , Anemia/economía , Eritropoyetina/administración & dosificación , Eritropoyetina/economía , Costos de la Atención en Salud/estadística & datos numéricos , Inyecciones Intravenosas/economía , Inyecciones Subcutáneas/economía , Anciano , Anemia/epidemiología , Femenino , Humanos , Inyecciones Intravenosas/estadística & datos numéricos , Inyecciones Subcutáneas/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Modelos Económicos , Ontario/epidemiologíaRESUMEN
BACKGROUND: Allergen-specific immunotherapy (AIT) is safe and effective for the treatment of allergic rhinitis and allergic asthma. However, patient non-compliance is a major barrier to achieving optimal outcomes Objective: To determine the level of compliance among patients using AIT and to identify factors associated with non-compliance Methods: A retrospective analysis using questionnaires was conducted to study compliance among 236 patients with allergic rhinitis with or without asthma who began AIT in 2009 or 2010 Results: The compliance rates at 3 y were 58.7% among patients on subcutaneous immunotherapy (SCIT) and 11.6% among those on sublingual immunotherapy (SLIT). The mean durations of treatment with SCIT and SLIT were 31 (+/-18.3) and 15.9 (+/-14.7) months, respectively. The most common causes of non-compliance among patients on SCIT were the frequency of injections (82.2%), the duration of treatment (70.9%), and commuting to the Allergy Center (67.7%). Reasons for non-compliance among patients on SLIT were related to inconvenience (43.4%), improvement without treatment (30.2%) and perception of poor efficacy (25.0%) Conclusion: Compliance with AIT is low, but at 3 years, it was higher among patients on SCIT than among patients on SLIT. Reasons for non-compliance include difficulty adjusting to treatment protocols and a perception that the efficacy is low. Patient education regarding the treatment course and the slow effect, as well as the need for close follow up to effectively prevent and treat adverse reactions, are important factors for improving compliance and treatment outcomes.
Asunto(s)
Asma/terapia , Desensibilización Inmunológica/estadística & datos numéricos , Cooperación del Paciente , Rinitis Alérgica/terapia , Adulto , Femenino , Humanos , Inyecciones Subcutáneas/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Inmunoterapia Sublingual/estadística & datos numéricos , Encuestas y Cuestionarios , Adulto JovenRESUMEN
New routes of administration available for some targeted therapies, especially subcutaneous injections, have an impact not only on the patients' daycare experience, but also on the unit's organization. This observational study conducted on 48 voluntary patients at the Institut universitaire du cancer Toulouse-Oncopole shows that the mean duration of the outpatient unit stay is diminished by one hour when a subcutaneous injection is used instead of an intravenous route. This duration decrease is mainly caused by an 82% average reduction in treatment duration. However, the waiting times before and after the treatment itself are not significantly impacted. Organizational methods related to the treatment prescription and preparation remain indeed the same. Anticipated prescription is not noticeably impacted either. This reduction of the duration of stay will truly be obtained if the whole unit's organization is adapted.
Asunto(s)
Antineoplásicos/administración & dosificación , Centros de Día/estadística & datos numéricos , Tiempo de Internación/estadística & datos numéricos , Terapia Molecular Dirigida/métodos , Instituciones Oncológicas/organización & administración , Instituciones Oncológicas/estadística & datos numéricos , Centros de Día/organización & administración , Composición de Medicamentos/estadística & datos numéricos , Humanos , Inyecciones Intravenosas/estadística & datos numéricos , Inyecciones Subcutáneas/estadística & datos numéricos , Terapia Molecular Dirigida/estadística & datos numéricos , Pacientes Ambulatorios , Factores de TiempoRESUMEN
INTRODUCTION: Proper insulin injection practice is essential for better diabetic control. This study aims to assess the insulin injection practice of patients with diabetes. MATERIALS AND METHODS: A cross-sectional study was conducted at Chitwan Medical College Teaching Hospital, Bharatpur, Nepal, from February 2017 to May 2017. Patients injecting insulin through insulin pens (n = 43) for a minimum of 4 weeks were consecutively recruited. Patients' baseline characteristics, current insulin injection technique, insulin transportation practice, complications of insulin injection, disposal practice of used needle, and acceptability of insulin were recorded. Descriptive statistics were performed using IBM-SPSS 20.0. RESULTS: The insulin injection technique of patients and their relatives was inadequate. The majority of patients and their relatives (25, 58.1%) mentioned that they transport their insulin cartridge without maintaining cold chain. Thirteen patients (30.2%, n = 43) reported complications of insulin injection and the most common complication among those patients was bruising (10, 76.9%, n = 13). Almost all patients disposed the used needle improperly, and the common method was disposing the needle in a dustbin and then transferring to municipal waste disposal vehicle. Insulin was accepted by just 16 (37.2%) patients. CONCLUSION: There was a significant gap between the insulin delivery recommendation through insulin pen and current insulin injection practice.
Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 1/epidemiología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/epidemiología , Sistemas de Infusión de Insulina/estadística & datos numéricos , Insulina/administración & dosificación , Estudios Transversales , Femenino , Conocimientos, Actitudes y Práctica en Salud , Humanos , Inyecciones Subcutáneas/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Nepal/epidemiología , Proyectos Piloto , Pautas de la Práctica en Medicina/estadística & datos numéricos , Centros de Atención Terciaria , Atención Terciaria de Salud/estadística & datos numéricosRESUMEN
AIM: To radiologically determine if intramuscular (IM) injections into the buttocks are truly intramuscular. MATERIALS AND METHODS: This was a prospective study conducted during a 6 month period beginning in October 2004. Fifty inpatients were recruited from a single tertiary referral hospital. Approval was obtained from the hospital research ethics committee and informed written consent was acquired from all participants. Prior to computerised tomography (CT), each patient received an IM injection of their prescribed medication along with 1 mL of air into the upper outer quadrant of the buttocks. CT images were subsequently analyzed by two radiologists to determine the position of the injected air bubble and to assess whether it was intramuscular or subcutaneous in position. Body mass index (BMI), distance to injection site, subcutaneous fat and muscle thickness were also measured. RESULTS: Overall, only 32% (n=16/50) of patients had intramuscular injections, with the majority of injections (68%, n=34/50) being subcutaneous. When analysed by gender, 56% (n=14/25) of males had intramuscular injections while in females, the efficacy rate was significantly lower at 8% (n=2/25). CONCLUSION: The majority of assumed intramuscular injections are actually subcutaneous.
Asunto(s)
Nalgas/diagnóstico por imagen , Adulto , Anciano , Anciano de 80 o más Años , Aire , Índice de Masa Corporal , Nalgas/anatomía & histología , Femenino , Humanos , Inyecciones Intramusculares/métodos , Inyecciones Intramusculares/estadística & datos numéricos , Inyecciones Subcutáneas/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Estudios Prospectivos , Distribución por Sexo , Grasa Subcutánea/diagnóstico por imagen , Tomografía Computarizada por Rayos X/métodosRESUMEN
BACKGROUND AND OBJECTIVE: Patients' perceptions and experiences of medication efficacy, medication adverse events, dosing frequency, and dosing complexity have been found to influence adherence to injectable disease-modifying treatments (DMTs) in patients with multiple sclerosis (MS). The aim of this study was to quantify patient preferences for features of injectable DMTs for MS. METHODS: Adult patients in the United States (US) with a self-reported diagnosis of MS completed an online discrete-choice experiment survey to assess preference for a number of features of a hypothetical injectable DMT. Patients chose hypothetical treatments in paired comparisons, where each treatment was described by features or attributes, including the number of years until disability progression, the number of relapses in the next 4 years, injection time, the frequency of injections, the occurrence of flu-like symptoms (FLS), and severity of injection-site reactions. Random-parameters logit regression parameters were used to calculate preference weights of attribute levels and the relative importance of changes in treatment features. RESULTS: Of the 205 patients who completed the survey, 192 provided sufficient data for analysis. The results indicated a broad range of tradeoffs that patients would be willing to make. With regard to this, the relative importance of an improvement in the number of years until disability progression from 1 to 2 (i.e., vertical distance between preference weights for these attribute levels) was 0.9 [95% confidence interval (CI) 0.5-1.2], the relative importance of this change was approximately equivalent to that of an improvement from 12 injections per month to two (mean 0.8, 95% CI 0.4-1.2), or approximately equivalent to a decrease from four to one relapses in the next 4 years (mean 0.8, 95% CI 0.5-1.2), or FLS 3 days after every injection to 3 days after some injections (mean 1.0, 95% CI 0.6-1.4). CONCLUSIONS: These results suggest that an improvement in treatment efficacy may be as important as a reduction in injection frequency or a reduction in some adverse events for patients who self-administer injectable DMTs for MS. Understanding the preferences of patients who use injectable treatments will inform the development of such treatments, which may in turn improve patient medication adherence and well-being.